search
Back to results

Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique (HOXB13_Mart)

Primary Purpose

Prostate Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Martinique
Study Type
Interventional
Intervention
HOXB13 c.853delT mutation
Sponsored by
University Hospital Center of Martinique
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Prostate Cancer focused on measuring Prostate cancer, Martinique, HOXB13 c.853delT prevalence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult man over 18 years of age living in Martinique with a prostate cancer whatever the histological type and the stage, managed in urology consultation (public and private sectors of Martinique)
  • Sporadic or familial form
  • Informed with a written consent signed by the participant and the investigator
  • Affiliate or beneficiary of french social security.

Exclusion Criteria:

  • Patient who is not of African descent
  • Refusal to participate.
  • Patients not affiliated to french social security

Sites / Locations

  • Centre Hospitalier Universitaire de MartiniqueRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

HOXB13 c.853delT mutation

Arm Description

Mutation is detected using Next Generation Sequencing (NGS) technique

Outcomes

Primary Outcome Measures

Estimation of prevalence of Allelic frequency of the HOXB13 c.853delT mutation
Mutation is detected using Next Generation Sequencing (NGS) technique

Secondary Outcome Measures

Full Information

First Posted
February 1, 2022
Last Updated
October 16, 2023
Sponsor
University Hospital Center of Martinique
search

1. Study Identification

Unique Protocol Identification Number
NCT05231915
Brief Title
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique
Acronym
HOXB13_Mart
Official Title
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 9, 2021 (Actual)
Primary Completion Date
April 9, 2025 (Anticipated)
Study Completion Date
April 9, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Center of Martinique

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In Martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms. We identified a rare heterozygous germline variant c.853delT (p.Ter285Lysfs) rs77179853, reported only among patients of African ancestry with a minor allele frequency of 3.2%. We search to estimate the prevalence of this variant in a sample of prevalent prostate cancer cases managed in urology consultation in Martinique .
Detailed Description
In Martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms. Despite the demonstration of a strong familial component, identification of the genetic basis for hereditary prostate cancer is challenging. The screening of the HOXB13 gene is recommended for men who develop an early-onset and/or familial Pca . In fact, the HOXB13 germline variant G84E (rs138213197) was described in men of European descent with prostate cancer risk. Other germline variants were detected in ethnic groups. More recently, we reported a rare HOXB13 mutation, specifically c.853delT (pTer285Lysfs) that appears to be contribute to young Prostate Cancer cases in Martinique. This variant is a stop loss reported only among patients of African ancestry . Regarding the allele frequency of the HOXB13 c.853delT variant observed in the Pca cohort, it will be necessary to assess relative and absolute Pca risks for HOXB13 c.853delT carriers. This information is essential to use this variant in genetic counseling. We propose to sequence the HOXB13 gene of all prostate cancers cases managed in urology consultation in Martinique.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
Prostate cancer, Martinique, HOXB13 c.853delT prevalence

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
465 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HOXB13 c.853delT mutation
Arm Type
Other
Arm Description
Mutation is detected using Next Generation Sequencing (NGS) technique
Intervention Type
Genetic
Intervention Name(s)
HOXB13 c.853delT mutation
Intervention Description
Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
Primary Outcome Measure Information:
Title
Estimation of prevalence of Allelic frequency of the HOXB13 c.853delT mutation
Description
Mutation is detected using Next Generation Sequencing (NGS) technique
Time Frame
At baseline

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult man over 18 years of age living in Martinique with a prostate cancer whatever the histological type and the stage, managed in urology consultation (public and private sectors of Martinique) Sporadic or familial form Informed with a written consent signed by the participant and the investigator Affiliate or beneficiary of french social security. Exclusion Criteria: Patient who is not of African descent Refusal to participate. Patients not affiliated to french social security
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Régine MARLIN
Phone
+596 596 30 67 35
Email
regine.marlin@chu-martinique.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Mickaëlle ROSE
Phone
+596 596 59 26 23
Email
mickaelle.rose@chu-martinique.fr
Facility Information:
Facility Name
Centre Hospitalier Universitaire de Martinique
City
Fort-de-France
ZIP/Postal Code
97261
Country
Martinique
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Régine MARLIN, PhD
Phone
0596 30 67 35
Ext
+596
Email
regine.marlin@chu-martinique.fr
First Name & Middle Initial & Last Name & Degree
Mickaëlle ROSE, MsC
Phone
0596 59 26 23
Ext
596
Email
mickaelle.rose@chu-martinique.fr
First Name & Middle Initial & Last Name & Degree
Odile BERA
First Name & Middle Initial & Last Name & Degree
Johan ROSE-DITE-MODESTINE
First Name & Middle Initial & Last Name & Degree
Stefanos BOUGAS

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique

We'll reach out to this number within 24 hrs